RGLS - Regulus: It Is Finding Its Stride Despite Initial Setback In Targeting ADPKD
2024-04-10 12:51:42 ET
Summary
- Regulus Therapeutics Inc. achieved positive results in cohort 2 of phase 1b study, using RGLS8429 for patients with autosomal polycystic kidney disease; Improvement of PC1 & PC2 proteins and reduction of cysts.
- Additional results from cohort 3 of phase 1b study, using RGLS8429 for patients with ADPKD, expected in mid-2024; Higher dose of 3 mg/kg of drug being deployed for this cohort.
- Highly positive Type D meeting held with FDA and stated that a single phase 2 study could be used for an Accelerated Approval of RGLS8429 for ADPKD.
- Completion of an oversubscribed $100 million private placement agreement will give it a cash runway into the 1st half of 2026.
Regulus Therapeutics Inc. ( RGLS ) is advancing the use of its drug RGLS8429 for the treatment of patients with autosomal dominant polycystic kidney disease [ADPKD] in an ongoing phase 1b study. It recently reported positive results from cohort 2 of this study using this drug to treat this patient population....
Regulus: It Is Finding Its Stride Despite Initial Setback In Targeting ADPKD